Appendix C

Biographical Sketches of Workshop Speakers and Moderators

Franck Berthe, D.V.M., Ph.D., is a senior livestock specialist in the Agriculture Global Practice of the World Bank and the coordinator of the Livestock Global Alliance since March 2016. The Alliance brings together the Food and Agriculture Organization of the United Nations, the International Fund for Agriculture Development, the International Research Institute on Livestock, the World Organisation for Animal Health (OIE), and the World Bank—five global public institutions committed to safer, fairer, and more sustainable livestock. Dr. Berthe was previously head of the Animal and Plant Health Unit at the European Food Safety Authority based in Parma, Italy. His core activity was to assess animal and plant production systems and practices with respect to primary production, ecosystems, and public health. Dr. Berthe’s job was to provide scientific advice to the EU risk managers and decision makers on a wide range of risks at the human–animal–ecosystem interface. Prior to coming to Italy in 2007, Dr. Berthe was associate professor at the Atlantic Veterinary College (UPEI) and Canada Research Chair in aquatic health sciences, exploring host pathogens relations in their environment. From 1994 to 2004 Dr. Berthe led active research in aquatic animal health at the French institute for the exploitation of the sea (IFREMER) in France and overseas territories. Dr. Berthe is vice president of the Biological Standards Commission of OIE. He has served on OIE specialized commissions since 1996. A native of France, Dr. Berthe received a doctorate of veterinary medicine and a Ph.D. degree in molecular parasitology. He has a diploma in bacteriology from the Pasteur Institute.

Elizabeth Cameron, Ph.D., is the Nuclear Threat Initiative’s (NTI’s) vice president for global biological policy and programs. Dr. Cameron previously served as the senior director for global health security and biodefense on the White House National Security Council staff, where she was instrumental in developing and launching the Global Health Security Agenda and addressed homeland and national security threats surrounding biosecurity and biosafety, biodefense, emerging infectious disease threats, biological select agents and toxins, dual-use research, and bioterrorism. From 2010 to 2013, Dr. Cameron served as office director for Cooperative Threat Reduction (CTR) and senior advisor for the Assistant Secretary of Defense for nuclear, chemical, and biological defense programs. In this role, she oversaw the implementation of the geographic expansion of the Nunn-Lugar CTR program. For her work, she was awarded the Office of the Secretary of Defense Medal for Exceptional Civilian Service. From 2003 to 2010 Dr. Cameron oversaw the expansion of U.S. Department of State Global Threat Reduction programs and supported the expansion and extension of the Global Partnership Against the Spread of Weapons and Materials of Mass Destruction, a multilateral framework to improve global chemical, biological, radiological, and nuclear security. Dr. Cameron served as an American Association for the Advancement of Science fellow in the health policy office of Senator Edward M. Kennedy where she worked on the Patients’ Bill of Rights, medical privacy, and legislation to improve the quality of cancer care. From 2001 to 2003, she served as a manager of policy research for the American Cancer Society. Dr. Cameron holds a Ph.D. in biology from the Human Genetics and Molecular Biology program at Johns Hopkins University and a B.A. in biology from the University of Virginia. Dr. Cameron is a member of the Council on Foreign Relations.

Carlos Castillo-Chavez, Ph.D., M.S., is a Regents professor; the Joaquin Bustoz, Jr., Professor of Mathematical Biology; a distinguished sustainability scientist; and the founding director of the Simon A. Levin Mathematical and Computational Modeling Sciences Center (SAL-MCMSC) at Arizona State University (ASU). He has co-authored more than 250 publications and a dozen books, textbooks, research monographs, and edited volumes. He was born in Mexico City, immigrating to the United States in 1974. Dr. Castillo-Chavez received his bachelor’s, master’s, and Ph.D. degrees from three campuses of the University of Wisconsin (UW) Stevens Point, Milwaukee, and Madison, respectively. He reached the rank of full professor at Cornell University in 1997 where he spent 18 years before moving to ASU in 2004. During his 30 years in academia, he has mentored 25 postdoctoral students. His 46 Ph.D. students include 21 women, 26 from U.S. underrepresented groups, and 7 from Latin America. He has been a research co-mentor to nearly 500 undergraduates. According to the

mathematics genealogy project, Dr. Castillo-Chavez is among the top 200 mentors of Ph.D. students in the history of mathematics. Recognitions to his work include: three White House awards (1992, 1997, and 2011), the 12th American Mathematical Society Distinguished Public Service Award in 2010, the 2007 American Association for the Advancement of Science (AAAS) Mentor award, and the 17th recipient of the Society for Industrial and Applied Mathematics (SIAM) Prize for Distinguished Service to the Profession and Distinguished Alumni by UW Stevens Point. He is a fellow of the AAAS, SIAM, founding fellow of the American Mathematical Society (AMS), and American College of Epidemiology (ACE). He has held honorary professorships at Xi’an Jiatong University in China, the Universidad de Belgrano in Argentina, and East Tennessee State University. Past appointments include a Stanislaw M. Ulam Distinguished Scholar at Los Alamos National Laboratory, a Cátedra Patrimonial at the Universidad Nacional Autónoma de México in México, and a Martin Luther King Jr. Professorship at the Massachusetts Institute of Technology. He was a member of the Board of Higher Education at the National Academy of Sciences (2009–2015) and served on President Barack Obama’s Committee on the National Medal of Science (2010–2015). He holds external current faculty appointments at Cornell University (since 2004), Santa Fe Institute (since 2005), and Universidad de Los Andes, Colombia (since 2016). His research lives at the interface of disease evolution, behavioral epidemiology, social dynamics, homeland security, epidemiology, addiction, and sustainability. He is the recipient of the inaugural Dr. William Yslas Outstanding STEM in Higher Education Award in 2015, given by the Victoria Foundation and co-sponsored by the Pasqua Yaqui Tribe of Arizona. Dr. Castillo-Chavez was elected member-at-large of the Section on Mathematics of the AAAS (February 2016–February 2020). On February 24, 2016, the University Francisco Gavidia inaugurated the “Centro de Modelaje Matemático Carlos Castillo-Chavez” in the City of San Salvador, El Salvador. He has been appointed to the National Science Foundation’s (NSF’s) Advisory Committee for Education and Human Resources (2016–2019) and is a member of NSF’s Advisory Committee for Cyberinfrastructure. He has been named George Polya Lecturer for 2017–2018. Dr. Castillo-Chavez has been the recipient throughout his academic career of grants by the NSF, the National Institutes of Health, Department of Defense, the Department of Agriculture (Hatch), and the Sloan Foundation. He also held the position of Rector of Yachay Tech University in Ecuador (2016–2018), an appointment made by former President Rafael Correa Delgado.

Mukesh Chawla, Ph.D., is advisor for health, nutrition, and population at the World Bank and coordinator of the Pandemic Emergency Financing Facility. He has worked for more than 20 years with governments and

international development partners in Africa, Asia, and Europe on a variety of health-sector issues. His current area of interest and responsibility is helping countries get better prepared to respond immediately and effectively to disease outbreaks that have the potential of assuming pandemic proportions. He has written extensively on the role of markets and marketlike institutions in the creation of incentives that strengthen health systems, fiscal space for health, innovations in health financing, design of health-sector reforms, and economics of aging populations. Prior to joining the Bank, he held a research faculty position at Harvard University. Before that, as member of the Indian Administrative Service in India, he held several key government positions between 1980 and 1998. He attended St. Stephen’s College and Delhi School of Economics in India, and Boston University.

Thomas B. Cueni, M.A., has been director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) since February 1, 2017. Prior to joining IFPMA he was secretary general of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years Mr. Cueni has been involved in the work of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he most recently served as vice chair of the European Markets Committee and association representative on the board. He represented the industry on the European Union (EU) High-Level Pharmaceutical Forum, was chairman of EFPIA’s Economic and Social Policy Committee, and chairman of the EFPIA Task Force on the EU Commission’s Pharmaceutical Sector Inquiry. Mr. Cueni also represented Interpharma, which he successfully transformed from the association of Swiss Rx companies to the association of pharmaceutical research companies in Switzerland, on the Council of IFPMA. Prior to his appointment with Interpharma, Mr. Cueni had a career as a journalist, inter alia, as London correspondent for the Basler Zeitung and Der Bund, and he served as a Swiss career diplomat with postings in Paris (Organization for Economic Co-operation and Development) and Vienna (International Atomic Energy Agency, United Nations Industrial Development Organization). He studied at the University of Basel, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has master’s degrees in economics (University of Basel) and politics (London School of Economics).

Peter Daszak, Ph.D., is president of EcoHealth Alliance, a U.S.-based organization that conducts research and outreach programs on global health, conservation, and international development. Dr. Daszak’s research has been instrumental in identifying and predicting the effect of emerging diseases across the globe. His achievements include identifying the bat origin of SARS, identifying the underlying drivers of Nipah and Hendra virus

emergence, producing the first ever global emerging disease “hotspots” map, developing a strategy to find out how many unknown viruses exist that could become pandemic, identifying the first case of a species extinction attributable to disease, and discovering the disease chytridiomycosis as the cause of global amphibian declines. Dr. Daszak is a member and chair of the National Academies of Sciences, Engineering, and Medicine’s Forum on Microbial Threats. He is a member of the National Research Council (NRC) Advisory Committee to the U.S. Global Change Research Program, the Supervisory Board of the One Health Platform, the One Health Commission Council of Advisors, the Center of Excellence for Emerging and Zoonotic Animal Diseases External Advisory Board, the Cosmos Club, and the Advisory Council of the Bridge Collaborative. He served on the Institute of Medicine committee on global surveillance for emerging zoonoses, the NRC committee on the future of veterinary research, the International Standing Advisory Board of the Australian Biosecurity Cooperative Research Centres, and has advised the Director for Medical Preparedness Policy on the White House National Security Staff on global health issues. Dr. Daszak is a regular advisor to the World Health Organization (WHO), World Organisation for Animal Health, and the Food and Agriculture Organization of the United Nations, and is actively involved in the WHO expert group on Public Health Emergency Disease Prioritization. Dr. Daszak won the 2000 Commonwealth Scientific and Industrial Research Organisation medal for collaborative research on the discovery of amphibian chytridiomycosis, is the EHA institutional lead for USAID-EPTPREDICT, is on the editorial boards of Conservation Biology, One Health, and Transactions of the Royal Society of Tropical Medicine & Hygiene, and is editor-in-chief of the journal EcoHealth. He has authored more than 300 scientific papers, and his work has been the focus of extensive media coverage, ranging from popular press articles to television appearances.

Anas El Turabi, B.M.Ch.B., M.Phil., is a Frank Knox fellow and doctoral candidate in health policy at Harvard University and an honorary visiting fellow at the Department of Public Health and Primary Care at the University of Cambridge. He received his B.A. with honors in physiological sciences and his medical degree from the University of Oxford, and an M.Phil. with distinction in clinical science from the University of Cambridge, where he completed the academic residency program in primary care. He has held fellowships at the University of Cambridge, RAND Europe, and Harvard University and has worked in health policy and global health at the Department of Health in England and with the World Health Organization. His current research involves applying statistical and computational methods to large health and economic datasets to better understand the economics of infectious disease crises, with the goal of informing global responses to pan-

demic risk reduction. He has previously supported the National Academy of Medicine’s Commission for a Global Health Risk Framework for the Future and the World Bank’s International Working Group on Financing Preparedness, developing estimates of the expected economic impact of pandemics, working on methods to assess economic vulnerability to infectious disease crises, and developing the investment case for improving global and national preparedness functions. He is a practicing primary care physician and sits on the General Practice Reference Group of the United Kingdom’s National Institute for Health and Care Excellence and the International Evaluation Advisory Committee of the Ontario Brain Institute.

Keiji Fukuda, M.D., M.P.H., is the director and a clinical professor at The University of Hong Kong School of Public Health. He previously worked at the World Health Organization (WHO) in several capacities including assistant director general (ADG) and special representative of the director general for antimicrobial resistance; ADG for the Health Security and Environment Cluster; and director of the Global Influenza Programme. Before that, he worked at the U.S. Centers for Disease Control and Prevention (CDC) as the Epidemiology Section chief, Influenza Branch, and as a medical epidemiologist in the Viral Exanthems and Herpesvirus Branch, National Center for Infectious Diseases. Dr. Fukuda has been a global public health leader in many areas including health security; emerging infectious diseases including seasonal, avian and pandemic influenza, severe acute respiratory syndrome, Middle East respiratory sydrome, and Ebola; antimicrobial resistance; development of the Pandemic Influenza Preparedness Framework; implementation of the International Health Regulations; food safety; and chronic fatigue syndrome. He has considerable experience in epidemiological research and field investigations, media communications, and international diplomatic negotiations including those held to establish a historic heads of state-level meeting on antimicrobial resistance at the United Nations in 2016. He has a B.A. in biology, an M.D., an M.P.H., was trained in the Epidemic Intelligence Service at CDC, and is certified in internal medicine by the American Board of Internal Medicine.

Andreas Gilsdorf, M.D., Dr.med., is an independent consultant on public health security. Until the end of 2017 he was the head of the Surveillance Unit and deputy head of the Department of Infectious Disease Epidemiology at the Robert Koch Institute (RKI), the German national public health institute. Dr. Gilsdorf is a physician with a specialization in occupational medicine and infectious disease epidemiology. From 2006 to 2008 he worked at the World Health Organization (WHO) Regional Office for Europe in Copenhagen, Denmark, on communicable disease surveillance and response. At RKI, he was responsible for the national infectious disease

surveillance system and represented the institute internationally, including at WHO as the focal point for the International Health Regulations (IHR), at the European Commission, and at the European Centre for Disease Prevention and Control. Dr. Gilsdorf was in charge of preparedness and response and built up and headed the Emergency Operations Centre at RKI. In 2017, his team had the technical lead at the G20 health ministers’ emergency exercise during their summit in Germany. Since 2018, he has been working as a consultant for public health security, focusing on strengthening IHR, intersectoral collaboration, preparedness, and emergency response operations.

Katharina Hauck, Ph.D., is an expert in the economics of infectious diseases, with specific research interests in the economics of HIV/AIDS, economic impact of epidemics, evaluation of complex public health, and health care interventions; cost-effectiveness analysis and priority setting; health system performance; and the role of individuals’ behaviors in the transmission of infectious disease. Dr. Hauck is a senior lecturer in health economics at the Department of Infectious Disease Epidemiology, Imperial College London. She is also a member of the “Global Health” and “Health Care Delivery Systems” Expert Networks of the World Economic Forum, co-chair for economics of the Global Fund Modelling Secretariat, and member of the International Decision Support Initiative.

Tania Zulu Holt, M.Sc., is a partner at McKinsey and Co. She started her career in the London office and subsequently relocated to Johannesburg in 2010 to pursue her passion for the continent and help expand McKinsey’s activities in health care across Africa. She leads McKinsey’s health care activities across Africa, motivated by a personal passion for extending access to affordable and high-quality health care services and products. She works at the intersection between private companies, governments, and social stakeholders across the whole continent, and has on-the-ground experience across 20 countries to date. Ms. Holt is passionate about diversity in organizations and is a co-author of McKinsey’s highly acclaimed Women Matter Africa report that shows that companies with a greater share of women on their boards of directors and executive committees tend to perform better financially. Prior to joining McKinsey, she worked with the Danish Ministry of Health.

Thomas V. Inglesby, M.D., is the director of the Center for Health Security of the Johns Hopkins Bloomberg School of Public Health. The Center for Health Security is dedicated to protecting people’s health from the consequences of epidemics and disasters. Dr. Inglesby is also professor in the Department of Environmental Health and Engineering in the Johns

Hopkins Bloomberg School of Public Health with a joint appointment in the Johns Hopkins School of Medicine. Dr. Inglesby’s work is internationally recognized in the fields of public health preparedness, pandemic and emerging infectious disease, and prevention of and response to biological threats. He is chair of the Board of Scientific Counselors, Office of Public Health Preparedness and Response, U.S. Centers for Disease Control and Prevention (CDC). He is also chair of the National Advisory Council of the Robert Wood Johnson Foundation’s National Health Security Preparedness Index. He was a member of the CDC Director’s External Laboratory Safety Workgroup that examined biosafety practices of CDC, the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) following high-profile laboratory incidents in federal agencies. He was on the 2016 Working Group assessing U.S. biosecurity on behalf of the President’s Council of Advisors on Science and Technology (PCAST). He has served on committees of the Defense Science Board, the National Academies of Sciences, the Institute of Medicine, and in an advisory capacity to NIH, Biomedical Advanced Research and Development Authority, Department of Homeland Security, and Defense Advanced Research Projects Agency. Dr. Inglesby has authored or co-authored more than 115 publications, including peer-reviewed research, reports, and commentaries on issues related to health security and preparedness for epidemics, biological threats, and disasters. He is editor-in-chief of the peer-reviewed journal Health Security, which he helped establish in 2003. He was a principal editor of the JAMA book Bioterrorism: Guidelines for Medical and Public Health Management. He has been invited to brief White House officials from the past four presidential administrations on national biosecurity challenges and priorities, and he has delivered congressional testimony on a number of issues related to public health preparedness and biosecurity. He is regularly consulted by major news outlets for his expertise. He is a member of the Board of Directors of PurThread, a company dedicated to developing antimicrobial textiles. Dr. Inglesby completed his internal medicine and infectious diseases training at the Johns Hopkins University School of Medicine, where he also served as assistant chief of service in 1996–1997. Dr. Inglesby received his M.D. from Columbia University College of Physicians and Surgeons and his B.A. from Georgetown University. He sees patients in a weekly infectious disease clinic.

Dean T. Jamison, Ph.D., is emeritus professor in the Institute for Global Health Sciences at the University of California, San Francisco (UCSF). In addition to UCSF, Dr. Jamison has been with University of California, Los Angeles, and the University of Washington and served as the T & G Angelopoulos Visiting Professor in the Harvard Kennedy School and the Harvard T.H. Chan School of Public Health (2006–2008). He previously worked at

the World Bank as a research economist and as manager of the Education Policy Division and of the Health, Nutrition, and Population Division. He was lead author for the bank’s 1993 World Development Report, Investing in Health. Dr. Jamison studied at Stanford (M.S., engineering science) and at Harvard (Ph.D., economics, under K. J. Arrow). In 1994 he was elected to membership in the National Academy of Medicine of the U.S. National Academies of Sciences, Engineering, and Medicine. Dr. Jamison served as co-chair with Lawrence H. Summers of the Lancet Commission on Investing in Health (The Lancet, December 2013). Most recently, he led work on the nine-volume Disease Control Priorities series from the World Bank and was lead author of its synthesizing publication (The Lancet, December 2017).

Rebecca Katz, Ph.D., M.P.H., is an associate professor of international health and co-director of the Center for Global Health Science and Security at Georgetown University. Prior to coming to Georgetown, she spent 10 years at George Washington University as faculty in the Milken Institute School of Public Health. Her research is focused on global health security, public health preparedness, and health diplomacy. Since 2007, much of her work has been on the domestic and global implementation of the International Health Regulations. Since 2004, Dr. Katz has been a consultant to the U.S. Department of State, working on issues related to the Biological Weapons Convention, pandemic influenza, and disease surveillance. Dr. Katz received her undergraduate degree from Swarthmore College, an M.P.H. from Yale University, and a Ph.D. from Princeton University.

Jonathan Kfoury, S.M., is a managing director and partner in L.E.K. Consulting’s San Francisco office, focused on biopharmaceuticals, medical technology, and life sciences. He joined the firm in 2006, and since that time has led an extensive set of engagements with global biopharmaceutical, medical technology, and diagnostic clients across human health, animal health, and agribusiness markets. Mr. Kfoury advises clients on commercial strategy and life cycle management for inline products, market access, and commercialization planning for pipeline assets, and growth and partnering strategy. With an operating background in both clinical and business development at specialty biopharmaceutical companies, Mr. Kfoury brings a hands-on understanding of internal decision making needs to his advisory work with clients. In addition to significant experience in immunology, oncology, men’s and women’s health, and central nervous system pain management, Mr. Kfoury’s interests include growth strategy for antibiotics and infectious diseases, biosimilars, and digital health opportunities. He has published and spoken extensively across the industry on the crisis of antimicrobial resistance, barriers to investment into novel antibiotics, public–private part-

nerships, and key opportunities for pharmaceutical, vaccine, and diagnostic manufacturers within anti-infectives more broadly. Prior to joining L.E.K., Mr. Kfoury was a business development executive for Acusphere and Purdue Pharma, and manager of global clinical development for Cubist Pharmaceuticals’ (now Merck’s) blockbuster antibiotic Cubicin—the most successful intravenous antibiotic launched in U.S. history. In addition to global management training at INSEAD, Mr. Kfoury earned an S.M. in health policy and management from Harvard University and graduated from Trinity College with a bachelor of science degree in neuroscience.

Ramanan Laxminarayan, Ph.D., M.P.H., is director and senior fellow at the Center for Disease Dynamics, Economics & Policy (CDDEP) in Washington, DC, and a senior research scholar and lecturer at the Princeton Environmental Institute at Princeton University. He is an affiliate professor at the University of Washington and a visiting professor at the University of Kwazulu Natal and the University of Strathclyde. Dr. Laxminarayan is founder of HealthCube, which works to improve access to health care and diagnostics worldwide. Since 1995, Dr. Laxminarayan has worked to improve the understanding of antibiotic resistance as a problem of managing a shared global resource. His work encompasses extensive peer-reviewed research, public outreach, and direct engagement in 11 countries in Asia and Africa through the Global Antibiotic Resistance Partnership. Through his prolific research, active public outreach (including a TED talk that has been widely viewed), and sustained policy engagement, he has played a central role in bringing the issue of drug resistance to the attention of leaders and policy makers worldwide and to the United Nations General Assembly in September 2016. Dr. Laxminarayan has served on the U.S. President’s Council of Advisors on Science and Technology’s antimicrobial resistance working group and is currently a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance. He is a series editor of the Disease Control Priorities for Developing Countries, 3rd edition.

Katherine D. Lee, Ph.D., is an applied environmental and natural resource economist. Her research primarily explores feedback between humans and natural systems and implications for resource managers and policy makers. Applications of her work include managing environmental uncertainty, biological invasions, conservation, and sustainable agriculture. Dr. Lee received her Ph.D. in economics from the University of Wyoming and a B.S. in economics and biology from the University of Wisconsin–Madison. She worked as a biological research technician in the Belovsky Lab at the University of Notre Dame from 2008 to 2011. Her work experience highlighted the importance of communicating ideas and results between

researchers, resource managers, and the public, and is the basis for her multidisciplinary approach to research.

Martin I. Meltzer, Ph.D., is lead of the Health Economics and Modeling Unit (HEMU), and a distinguished consultant in the Division of Preparedness and Emerging Infections, U.S. Centers for Disease Control (CDC) in Atlanta, Georgia. He received his undergraduate degree from the University of Zimbabwe in 1982, and master’s and doctorate in applied economics degrees from Cornell University, in 1987 and 1990, respectively. From 1990 to mid-1995, he was on the faculty at the College of Veterinary Medicine at the University of Florida. In 1995, he moved to CDC, where he was in the first class of Prevention Effectiveness Fellows (health economist). He led the modeling teams supporting CDC’s response to the 2009 H1N1 influenza pandemic, including producing monthly estimates of cases, hospitalizations, and deaths, as well as estimating effect of the vaccination program and use of influenza antiviral drugs. Other responses in which he led the modeling activities include estimating the residual risk associated with the 2012 contaminated steroid injectable products that caused fungal meningitis among patients, the 2014–2015 Ebola epidemic in West Africa, and the Zika epidemic. Examples of his research include estimating the effect of the 2009 influenza pandemic, the modeling of potential responses to smallpox as a bioterrorist weapon, and assessing the economics of controlling diseases such as rabies, dengue, hepatitis A, meningitis, Lyme, and malaria. Dr. Meltzer has published approximately 300 publications, including more than 140 papers in peer-reviewed scientific journals and more than 50 software tools. These tools include FluAid, FluSurge, and FluWorkLoss, designed to help state and local public health officials plan and prepare for catastrophic infectious disease events. They have been downloaded more than 130,000 times and have been used by local, state, national and international public health agencies with jurisdictions exceeding a total of 1 billion people. He is an associate editor for Emerging Infectious Diseases. He also supervises a number of postdoctoral health economists at CDC.

Suerie Moon, Ph.D., M.P.A., is director of research at the Global Health Centre, Graduate Institute of International and Development Studies, Geneva, and adjunct lecturer on global health at the Harvard T.H. Chan School of Public Health. She has served on a number of advisory bodies, including most recently the World Health Organization Fair Pricing Forum Advisory Group, Expert Advisory Group to the United Nations Secretary-General’s High-Level Panel on Access to Medicines, and Proposal Review Committee of UNITAID. Prior to joining the Graduate Institute, she was study director of the Harvard-London School of Hygiene & Tropical Medicine Independent Panel on the Global Response to Ebola, and cofounded

and led the Forum on Global Governance for Health, a focal point at Harvard University for research, debate, and strategic convening on issues at the intersection of global governance and health. Her research and teaching focus on global governance, the political economy of global health (focusing on innovation and access to medicines; outbreak preparedness and response; trade, investment, and intellectual property rules; and development assistance for health), the evolution of international regimes, and innovative policies for addressing global problems. She received a B.A. from Yale, an M.P.A. from Princeton, and a Ph.D. from the Harvard Kennedy School of Government.

Tolbert G. Nyenswah, L.L.B., M.P.H., currently serves as the first director general of the National Public Health Institute of Liberia, an entity that was officially established on January 26, 2017, to prevent and control public health threats, post the 2014–2016 Ebola epidemic, that devastated Liberia’s public health system and resulted in more than 11,000 cases with close to 5,000 deaths in Liberia alone. Prior to his appointment as director general, Mr. Nyenswah became Liberia’s first deputy minister of health for disease surveillance and epidemic control, in the Department of Public Health, which was created within the Ministry of Health, after the World Health Organization’s (WHO’s) first declaration that Liberia was free of Ebola in the human population. He had been appointed incident manager of the Incident Management System, responsible for leading Liberia’s national Ebola response activities. Mr. Nyenswah has worked in the public health sector in Liberia for the past 18 years in the Ministry of Health and Social Welfare, now Ministry of Health, in several capacities, beginning as an office assistant in 1999. Since then, he rose to the position of assistant minister of health and deputy chief medical officer for Preventive Services (2012–2015), responsible for the prevention and control of communicable and noncommunicable diseases, as well as mental health. Before assuming this position, he was the deputy program manager of the National Malaria Control Program (2007–2011), overseeing the coordination of malaria control and prevention activities, and formulating policies and implementation strategies. He also served concurrently as the acting program manager for 2 years (2009–2011). As acting and deputy program manager, he was a senior malaria specialist, overseeing the nationwide distribution of millions of bed nets and the effective treatment of millions of malaria cases in Liberia. Under his leadership, malaria prevalence was substantially reduced from 66 percent in 2005 to 28 percent by 2011. Mr. Nyenswah was instrumental in the development of the first National Health Policy and National Health Plan for Liberia in 2007. Mr. Nyenswah has received several distinguished service awards. In March 2017, the U.S. Centers for Disease Control and Prevention presented him with an honor and award certificate from the

National Center for Emerging and Zoonotic Infectious Diseases. He was honored with the first Bloomberg Hopkins Emerging Leader Award, on September 19, 2016. This award was established by Bloomberg Philanthropies, in honor of the Johns Hopkins Bloomberg School of Public Health’s centennial celebration, to recognize a student or alumni with the potential to affect public health on a large scale for years to come. He also received the Outstanding Recent Graduate Award from the Johns Hopkins University Alumni Association in 2015, a distinction among more than 20,000 alumni globally. Additionally, the Johns Hopkins University Master of Public Health program graced him with a Certificate of Recognition in 2011. In 2015, Mr. Nyenswah was awarded one of the Liberia’s highest honors, the Grand Commander, Order of the Star of Africa, by President Ellen Johnson Sirleaf, during Liberia’s 168th Independence Day anniversary, for his service as the incident manager who coordinated the Incident Management System that brought the Ebola crisis under control in Liberia. Also in 2015, he received the Golden Image Award from Crusaders for Peace, a nongovernmental organization in Liberia. Mr. Nyenswah obtained the following degrees and certificates: Master of Public Health, Johns Hopkins Bloomberg School of Public Health (2012); Bachelor of Law, Louis Arthur Grimes School of Law, University of Liberia (2009); and Bachelor of Science (biology and chemistry), University of Liberia (2006). He has certificates and postgraduate diplomas in public health surveillance and population disease control, health and human rights, public health law, malaria in pregnancy, and global mental health, among others. Mr. Nyenswah is also a Doctor of Public Health candidate at the Johns Hopkins Bloomberg School of Public Health.

Mark Pearson, M.Sc., is deputy director for employment, labor, and social affairs (ELS) at the Organisation for Economic Co-operation and Development (OECD). Mr. Pearson works with the director to provide leadership in the coordination and management of the activities of ELS and ensure that it is at the forefront of the international social and employment agenda. Mr. Pearson joined OECD in 1992, initially working on tax issues. He then moved to ELS, becoming the head of the Social Policy Division from 2000 to 2008. During this time he initiated work on “Babies and Bosses,” “Pensions at a Glance,” and led the first cross-directorate work on gender and work on income inequality. In 2009 he became head of the Health Division where the central focus of work was on how to deliver health care with greater efficiency, including putting much more effort into prevention of obesity and harmful use of alcohol. Mr. Pearson has a degree in politics, philosophy, and economics from Oxford University and an M.Sc. in economics and econometrics from Birkbeck, University of London.

Paul Schaper, M.B.A., M.P.H., leads global policy efforts at Merck & Co., Inc., on infectious disease, including antibiotics and antifungals, HIV, and hepatitis, as well as on neuroscience. He represents Merck on the board of the AMR Industry Alliance, a coalition of biotechnology, diagnostics, generics, and research-based pharmaceutical companies and associations set up to work toward sustainable solutions to curb antimicrobial resistance. From 2013 to 2017, Mr. Schaper served as the board member for the Private Sector Constituency on the board of The Global Fund to Fight AIDS, Tuberculosis and Malaria. He currently serves as the Private Sector Alternate Board Member. Mr. Schaper earned his B.A. and master’s degrees in public health policy and business administration from Emory University and a master’s degree in clinical psychology from Georgia State University.

Lawrence H. Summers, Ph.D., is the Charles W. Eliot University Professor and president emeritus of Harvard University. During the past two decades, he has served in a series of senior policy positions in Washington, DC, including the 71st Secretary of the Treasury for President Clinton, director of the National Economic Council for President Obama, and vice president of development economics and chief economist of the World Bank. He received a bachelor of science degree from the Massachusetts Institute of Technology in 1975 and was awarded a Ph.D. from Harvard University in 1982. In 1983, he became one of the youngest individuals in recent history to be named as a tenured member of the Harvard faculty. In 1987, Dr. Summers became the first social scientist ever to receive the annual Alan T. Waterman Award of the National Science Foundation, and in 1993 he was awarded the John Bates Clark Medal, given every 2 years to an outstanding American economist under the age of 40. He is currently the Charles W. Eliot University Professor at Harvard University and the Weil Director of the Mossavar-Rahmani Center for Business and Government at Harvard’s Kennedy School.

Jami Taylor is a board advisor at Stanton Park Advisors, a Boston-based investment bank, where she oversees the firm’s capital raising and investor relations practices. Previously, Ms. Taylor was senior director of policy and partnerships within the Global Public Health division of Johnson & Johnson (J&J). In this role, she served as the designated J&J representative at major forums with international reach, including the Private Sector Delegation to The Global Fund to Fight AIDS, Tuberculosis and Malaria; the Partners Council at the Center for Global Development; and the Health Systems Leapfrogging Project of the World Economic Forum. A recognized expert in innovative financing for global health and development, Ms. Taylor secured a signature Blended Finance collaboration for J&J with Canada’s Department of Foreign Affairs, Trade, and Development in 2015,

which was highlighted at the Global Financing for Development conference in Addis Ababa. In 2016, she co-founded Financing & Innovation in Global Health, a platform to drive more efficient resource mobilization in global health research and development and delivery. She is also the founder of WinnDev, a network of women advancing innovative approaches to the poverty reduction. In 2014, Ms. Taylor was named a Cross-Sector Leadership Fellow at the Presidio Institute, a program created by the White House Office of Social Innovation and Civic Participation to advance the work of leaders addressing society’s most complex challenges. Prior to joining J&J, she spent more than 10 years in alliance development, policy communications, and grassroots mobilization. Her experience beyond industry includes work with the White House Office of Public Liaison, members of the U.S. Congress, and the U.S. Departments of Treasury, Commerce, and Health and Human Services to advance legislative and policy priorities on a nationwide scale. She is a published author and editor, and an alumna of the University of Virginia, Cornell University, Northwestern University, and Harvard University.

Kimberly Thompson, Sc.D., focuses her research and teaching on improving children’s lives and global health by integrating the best available evidence into health risk and policy models that inform decisions and improve management. She focuses on the issues related to developing and applying quantitative methods for risk assessment and risk management, and consideration of the public policy implications associated with including uncertainty, variability, and complex dynamics in risk characterization. Drawing on a diverse background, Dr. Thompson seeks to effectively integrate economic, social, political, legal, and technological issues into analyses that inform public policy and improve decision making in what she calls the “Age of Risk Management.” While on the faculty at the Harvard T.H. Chan School of Public Health, Dr. Thompson created and directed the Kids Risk Project. In January 2009, she incorporated Kid Risk, Inc. (www.kidrisk.org) as a self-standing, nonprofit organization that focuses on improving children’s lives by understanding, characterizing, and communicating about the real risks that children face around the world and on empowering policy makers, parents, kids, and others to use the best available information to make better decisions. Dr. Thompson joined the faculty of the College of Medicine at the University of Central Florida in September 2012 and served as professor of preventive medicine and global health. She maintains long-standing interests in pediatric risk analysis and the potential trade-offs associated with policies designed to protect children and adolescents. Dr. Thompson received her B.S. and M.S. in chemical engineering from the Massachusetts Institute of Technology and her doctor of science (Sc.D.) degree from the Harvard T.H. Chan School of Public Health.

She is a past president and fellow of the Society for Risk Analysis, which recognized her with its 2004 Chauncey Starr Distinguished Young Risk Analyst Award. In 2008, she received the Jay Wright Forrester Award from the System Dynamics Society for some of the Kids Risk Project’s research on polio. In 2014, Dr. Thompson led the U.S. Centers for Disease Control and Prevention/Kid Risk, Inc., team that won the Institute for Operations Research and the Management Sciences Edelman Award, the leading global prize in analytics and operations research for its collaborative work on global polio eradication. Dr. Thompson currently serves as the chair of the U.S. National Vaccine Advisory Committee.

Anna Vassall, Ph.D., is a professor in health economics at the London School of Hygiene & Tropical Medicine (LSHTM) and holds the Joep Lange Chair at the University of Amsterdam. She leads the economic evaluation and priority-setting group in global health at LSHTM. She is widely published and has led numerous large-scale economic analyses of tuberculosis (TB), HIV, and sexual and reproductive health interventions. She has substantial program experience directing health-sector development projects in several countries and supporting national strategic planning processes. She is a founding member of the TB Modelling Analysis Consortium and sits on the Strategic and Technical Advisory Group for the World Health Organization’s (WHO’s) Global TB Program (STAG-TB) and the Task Force on Catastrophic Cost Measurement for TB. She is a lead investigator of the Global Health Costing Consortium, a Bill & Melinda Gates Foundation–funded project to estimate HIV, TB, and other health service costs globally.

Ed Whiting, M.A., is responsible for Wellcome Trust’s work to influence policy makers around the world in support of their objectives, for example, that Brexit enables excellent international science to flourish, that they are improving the global capacity to respond to epidemics and antimicrobial resistance, and that Wellcome is supporting scientists and researchers to enable rapid take-up of their work where there is potential for a significant positive impact on health. As chief of staff, he is responsible for supporting the development of Wellcome’s new priority areas and how to deliver their existing priorities. He works closely with the chair and director to make sure they have identified and are delivering on top priorities and promises, and with other members of the executive leadership team to coordinate their big decisions. Before joining Wellcome in September 2016, Mr. Whiting worked in a number of Whitehall social and financial policy departments, including HM Treasury’s financial stability team during the 2008–2009 financial crisis. He was most recently at 10 Downing Street as deputy Principal Private Secretary to the Prime Minister, leading on public

services. Mr. Whiting was awarded the OBE for public service and services to 10 Downing Street in the June 2016 Queen’s Birthday Honours list.

Joanna Wolkowski, M.B.A., M.S., is vice president at Pfizer Inc. and lead of Portfolio & Decision Analysis (PDA). Her group is responsible for driving portfolio strategy and insight generation, enabled by innovative portfolio systems and robust reporting, to inform research and development investment decision making for Pfizer’s senior-most leaders. She was elevated to her current role after having led strategic and portfolio oversight within PDA for the Vaccines, Oncology, and Consumer business segments. Formerly, Ms. Wolkowski was a principal at the Boston Consulting Group in the Health Care Practice Area. Her experience focused on corporate and commercial strategy within the pharmaceutical industry, driving strategic recommendations across therapeutic areas at the highest levels of client organizations. Earlier in her career, Ms. Wolkowski worked for 6 years with Pfizer as a discovery chemist, pharmaceutical sales representative, and strategic management group consultant. While a discovery chemist, she was part of a team that discovered azetidinyl ketolides for the treatment of respiratory tract infections caused by susceptible and multidrug-resistant bacteria. She also previously worked with Sierra Nevada Brewing Company in their Sales and Marketing division. Ms. Wolkowski earned a B.A. in chemistry from Middlebury College, an M.S. in chemistry from Yale University, and an M.B.A. in health care management and strategic management from the Wharton School of the University of Pennsylvania.

This page intentionally left blank.